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Translational and Regulatory Challenges
for Exon Skipping Therapies
Annemieke Aartsma-Rus,1,2 Alessandra Ferlini,3 Nathalie Goemans,4 Anna M.G. Pasmooij,5,6
Dominic J. Wells,7 Katerine Bushby,2 Elizabeth Vroom,8 and Pavel Balabanov9
Abstract
Several translational challenges are currently impeding the therapeutic development of antisense-mediated exon
skipping approaches for rare diseases. Some of these are inherent to developing therapies for rare diseases, such
as small patient numbers and limited information on natural history and interpretation of appropriate clinical
outcome measures. Others are inherent to the antisense oligonucleotide (AON)-mediated exon skipping ap-
proach, which employs small modified DNA or RNA molecules to manipulate the splicing process. This is a
new approach and only limited information is available on long-term safety and toxicity for most AON chem-
istries. Furthermore, AONs often act in a mutation-specific manner, in which case multiple AONs have to be
developed for a single disease. A workshop focusing on preclinical development, trial design, outcome measures,
and different forms of marketing authorization was organized by the regulatory models and biochemical outcome
measures working groups of Cooperation of Science and Technology Action: ‘‘Networking towards clinical
application of antisense-mediated exon skipping for rare diseases.’’ The workshop included participants from
patient organizations, academia, and members of staff from the European Medicine Agency and Medicine
Evaluation Board (the Netherlands). This statement article contains the key outcomes of this meeting.
Introduction
Antisense-mediated exon skipping uses antisense oli-gonucleotides (AONs), small modified pieces of RNA
or DNA that can specifically hybridize with their target in the
pre-mRNA. Upon AON binding, the targeted sequence
(generally an exon or a cryptic exon) is hidden from the
splicing machinery and then spliced out with its flanking
introns, rather than included in the mature mRNA (Fig. 1).
Exon skipping can be exploited in many ways to correct for
the consequences of different genetic variations [for more
details, see (van Roon-Mom and Aartsma-Rus, 2012)]. Be-
cause of this versatility, many inherited rare diseases would
potentially benefit from this approach. However, developing
therapeutic approaches for rare diseases is challenging. Of-
ten, information about the natural history of the disease is
scarce, functional outcome measures have to be developed
and validated, patient numbers for clinical trials are small,
and there is no, or only limited, experience with conducting
clinical trials. AONs are a relatively recent development and
only limited information is available for long-term treatment
effects, and many newer AON chemistries have been tested
only in cell and animal models (van Roon-Mom andAartsma-
Rus, 2012). AONs often provide a personalized medicine
type of approach, where for each disease an AON often ap-
plies only to a subset of patients with a specific mutation,
providing even more of a challenge for trial design.
The Example of Duchenne Muscular Dystrophy
These challenges are showcased by efforts to develop ther-
apies for Duchenne muscular dystrophy (DMD) (Aartsma-Rus,
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2010), an X-linked disease caused by mutations (generally
deletions of one or more exons) that disrupt the reading frame
of the dystrophin transcript (Monaco et al., 1988). Dystrophin
normally has a function in providing muscle fibers with sta-
bility during contraction by connecting the actin cytoskeleton
of the fiber to the connective tissue layer surrounding the fiber.
Muscle fibers lacking dystrophin are very sensitive to damage
during regular exercise. In DMD patients, chronic muscle
damage leads to inflammation, replacement of muscle tissue by
fibrotic and adipose tissues, and loss of muscle functions
(Grounds, 2008).
With good care, most patients become wheelchair de-
pendent in their early teens, need assisted ventilation in their
late teens, and die because of respiratory or heart failure in
the second to fourth decade of life (Emery, 2002; Bushby
et al., 2010a,b). Cognitive problems are seen in one-third of
patients, but these are not progressive. Mutations that
maintain the reading frame can give rise to dystrophins that
are able to connect the actin cytoskeleton to the connective
tissue, although with a slightly altered linker. These dystro-
phins are partially functional, as showcased by the fact that
this type of mutation is found in the later onset and more
slowly progressive Becker muscular dystrophy (BMD)
(Monaco et al., 1988; Emery, 2002). Antisense-mediated
exon skipping for DMD aims to restore the disrupted dys-
trophin reading frame to allow production of a Becker-like
dystrophin (Fig. 1) (Aartsma-Rus, 2010). This is achieved by
AONs that target a specific exon in the pre-mRNA. Note that
different mutations require the skipping of different exons to
reframe the transcript (e.g., exon 51 skipping for a deletion of
exons 48–50, but exon 52 skipping for a deletion of exon 53),
and that skipping of any given exon applies only to a subset
of patients (Aartsma-Rus et al., 2009). Since exon 51 skip-
ping applies to the largest group of patients (13%), AONs
targeting exon 51 were the first to be developed clinically
(Aartsma-Rus, 2014b; Cirak et al., 2011; Goemans et al.,
2011; Mendell et al., 2013). Nevertheless, only a minority of
DMD patients would benefit from exon 51 skipping. AONs
to skip additional exons have to be developed to offer a
potential therapy for larger numbers of patients.
While certain groups are reasonably sized (e.g., exon 44,
45, and 53 skipping would apply to 6%, 8%, and 8% of
patients), skipping of some of the other exons would apply
only to very small groups of patients or even single mutations
(Aartsma-Rus et al., 2009). Each AON is considered a new
drug, posing a challenge on developing this approach for the
majority of patients. Furthermore, for 19% of patients, skip-
ping of a single exon is not sufficient to restore the reading
frame and double-exon skipping is required (Fig. 1C).
For exon 51 skipping, two different AON chemistries
have been tested in clinical trials (i.e., 2¢-O-methyl phos-
phorothioate [drisapersen] and phosphorodiamidate mor-
pholino oligmer [eteplirsen] AONs) (Cirak et al., 2011;
Goemans et al., 2011; Mendell et al., 2013; Aartsma-Rus,
2014b). For both chemistries, systemic dose-finding studies
followed by an open-label extension phase showed en-
couraging results as presented at scientific meetings, that is,
stabilization in walking distance measured in the 6min walk
test rather than the decline that would have been anticipated
based on natural history for the majority of patients in both
trials (Goemans et al., 2013; McDonald et al., 2013a; Pane
et al., 2014).
In a small phase 2 trial involving 12 patients, maintenance
of the 6min walk distance was observed for 10 patients for
over 2 years. The drisapersen-treated patients outperformed
placebo-treated patients in two phase 2 trials involving 5–13-
year-old patients (average 7.5) for the primary endpoint
(*30m difference in the 6min walk test). However, in a
larger phase 3 trial, involving also older, and more severely
affected patients (5–16 years, average 8.2 years), the differ-
ence between treated and placebo-treated patients was much
smaller, that is, a mean difference of*10m in favor of the
drisapersen-treated group. Notably, a lot of the natural history
data for this disease became available only while phase 2 and
3 trials were already ongoing. Furthermore, the analysis of
the open-label extension study following the phase 3 trial
suggests that longer treatment (96 weeks) may be required to
show benefit in more severely affected patients.
Of course, DMD is just one example and AON-mediated
exon skipping is also explored as a therapeutic option for
other diseases, such as the genetic skin blistering disorder
epidermolysis bullosa. Similarly to DMD, moderation of
phenotypic severity has been observed in patients with epi-
dermolysis bullosa through in-frame exon skipping of exons
containing nonsense or frame-shift mutations (McGrath
et al., 1999). While different genetic diseases pursuing exon
FIG. 1. Antisense-mediated exon skipping. (A) Duchenne muscular dystrophy is caused by mutations that disrupt the
open reading frame (a deletion of exons 48–50 in this example), while mutations that maintain the reading frame are
associated with a less severe disease course. Antisense oligonucleotides (AONs) specific for an exon (exon 51 in this
example) can hybridize to this exon and hide it from the splicing machinery, causing the exon to be spliced out with its
flanking introns and the reading frame to be restored. Different mutations require the skipping of different exons to restore
the reading frame. (B) A deletion of exon 53 can be reframed by exon 52 skipping. (C) A deletion of exons 46–50 requires
the skipping of both exon 45 and exon 51, as single exon 45 or single exon 51 skipping does not reframe the transcript.
886 AARTSMA-RUS ET AL.
skipping face similar challenges, each also faces specific
challenges, for example, because of the different tissues that
need to be targeted.
Furthermore, other therapeutic approaches are in develop-
ment for DMD as well. In fact, the week before our work-
shop took place, it was announced that the committee for
human medicinal products (CHMP) of the European Medicine
Agency (EMA) gave a positive opinion to the European
Commission for conditional approval of Translarna (ataluren)
for the treatment of DMD resulting from a nonsense mutation
in ambulatory patients aged 5 years and older. The European
Commission has since officially granted ataluren conditional
marketing authorization (August 4, 2014). The full conditions
of the marketing authorization and the related discussion, in-
cluding the need of a completed confirmatory phase III study,
can be found in the European Public Assessment Report and
the Annex II of the Summary of product characteristics for
Translarna (European Medicines Agency, 2014).
Like exon skipping, Translarna (previously PTC124)
aims to restore dystrophin, but it achieves this by stimulat-
ing read through of premature stop codons (*15% of DMD
patients carry premature stop codons in the dystrophin
gene). Translarna is the first drug to receive a conditional
market authorization by the European Commission for pa-
tients with DMD in the EU. As such, available data on the
clinical development of Translarna are useful when dis-
cussing DMD exon skipping, for which no marketing au-
thorization has yet been obtained.
Aim of the Workshop
The European Cooperation of Science and Technology
(COST) provides funding for networking to overcome scien-
tific and regulatory challenges. In this framework, COST
Action BM1207 receives funding to network toward clinical
application of antisense-mediated exon skipping for rare dis-
eases (Aartsma-Rus, 2014a). Representatives of the regulatory
models working group and biochemical outcome measures
working group met in Leiden, the Netherlands, on May 26,
2014, to discuss existing issues and possible ways forward for
the development of antisense-mediated exon skipping thera-
pies for rare diseases, focusing on trial design, outcome
measures, and market approval models as was done in a larger
meeting in 2009 (Muntoni, 2010). Although the scope of the
current workshop was to discuss the challenges for all rare
diseases, the focus often fell on DMD, because for this disease
the most data are available and the approach has been de-
veloped the furthest. This statement article contains the key
outcomes of this workshop.
Development Plan
AON-mediated exon skipping is generally tested first in
patient-derived cell models and animal models to obtain
proof of concept of the approach. AONs are mostly species
specific, meaning that the AONs tested in patient-derived
cells are not identical to those tested in mice. This can be
circumvented by developing a humanized mouse model,
which allows studying human-specific AONs in vivo
(Bremmer-Bout et al., 2004). In contrast to mandatory
safety studies, proof-of-concept studies in animal models are
not crucial to the process of obtaining marketing authori-
zation, provided that the field has a good understanding of
target engagement. However, especially when the pheno-
type of the model is close to the human disease, animal
model studies can be used to inform and guide clinical trial
design. Furthermore, the ability to provide proof of concept
in relevant animal models is always considered a valuable
step in the overall analysis of the totality of available data at
the time of marketing authorization.
When the observed clinical benefit is clear from the
performed confirmatory trials and the effect size is com-
pelling, the data on proof of concept in animal models may
be unnecessary. However, for most rare diseases (as seen for
DMD exon skipping in phase 2 and 3 trials), there is the risk
that the demonstrated effect size may generally be modest,
since trials are small and most therapies aim at slowing
down disease progression. In such cases, having supportive
preclinical data to demonstrate proof of concept in (hu-
manized) animal models can provide crucial additional
justification for the proposed therapeutic approach.
Traditionally, potential drugs are tested first in phase 1
trials in healthy volunteers, followed by dose-finding safety
phase 2 trials, and finally larger phase 3 placebo-controlled
trials aimed at confirming efficacy and safety and providing
the main dataset for the marketing authorization application.
For antisense-mediated exon skipping for DMD, the trials in
healthy volunteers have been omitted, reasoning that while
skipping an exon restores the reading frame for DMD pa-
tients, it will disrupt the reading frame in healthy volunteers.
Given that the half-life of dystrophin is *3 months (Wu
et al., 2012; Verhaart et al., 2014), and that the efficiency of
exon skipping in vivo with the AON chemistries tested in
clinical trial is not that high, it is unlikely that this would
lead to DMD in a healthy person. Furthermore, the phar-
macodynamics of AONs in healthy volunteers will differ
from those of DMD patients, whose muscles are more per-
meable because of the effect of the disease (Heemskerk
et al., 2010). For the AON chemistries currently in trial for
DMD (2¢-O-methyl phosphorothioate and phosphor-
odiamidate morpholino oligomer), safety data in human
subjects were already available, and therefore performing
studies in healthy volunteers would have provided only
limited new information, and would have slowed down
therapy development.
There are also many new AON chemistries currently in
development. Most of these have not yet been tested in
humans and for these performing safety tests first in healthy
volunteers could be considered. Notably, for dystrophin,
exon skipping is unlikely to negatively impact healthy
volunteers because of the long protein half-life and because
nonfunctional proteins are produced after exon skipping.
However, this may not be the case for exon skipping ap-
proaches for other diseases, for example, through inducing a
dominantly negative effect. Thus, whether or not to test
AONs in healthy volunteers will have to be decided on a
case-by-case basis.
Since most rare diseases represent a situation of unmet
medical need and are progressive and debilitating, the need
for placebo-controlled trials was debated. Using the example
of DMD, phase 2 trials for Translarna and drisapersen re-
vealed that the disease progression of the placebo group as
measured by the 6min walk test was very similar to the
natural history data (McDonald et al., 2013a; unpublished
data). This can be used as an argument to forego the placebo
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group in confirmatory clinical trials and use the natural
history data as a reference. While this may become an ac-
ceptable option for the regulators in the future, pending the
increased understanding of the disease based on most recent
data, for the moment, it seems that some form of placebo
treatment will be required to provide the regulators with a
more convincing proof that a relevant clinical benefit has
been demonstrated.
More specifically for DMD patients, a 30m improvement
over placebo measured by the 6min walk test was consid-
ered a clinically relevant benefit in the Translarna trial.
However, the disease progression is relatively slow; for
example, DMD patients generally lose *30m in the dis-
tance walked in 6min in 1 year (Goemans et al., 2013;
McDonald et al., 2013a; Pane et al., 2014), and it will take
time for the AONs to achieve their expected mechanism of
action (i.e., accumulation of sufficient amounts of dystro-
phin to lead to less sensitivity to contraction-induced muscle
damage, and a slower disease progression). This implies that
it is unlikely that placebo-controlled trials with a duration of
less than 1 year will be sensitive enough to show a clinically
relevant treatment effect.
For DMD using a 2:1 randomization for treatment (two
thirds) and placebo (one third) groups is commonly used
(e.g., eteplirsen [phase 2a], drisapersen [two phase 2 and
phase 3] and ataluren [phase 2b] trials). Given the hetero-
geneity of the disease severity and progression, trials should
include sufficient numbers in each group, as including small
patient numbers can lead to very biased results (Aartsma-
Rus and Muntoni, 2013; Goemans et al., 2013).
For DMD, results of natural history studies have been
published recently (Goemans et al., 2013; Henricson et al.,
2013a,b; Mazzone et al., 2013; McDonald et al., 2013a,b;
Pane et al., 2014). This information should be useful to set
inclusion criteria and select the group most likely to show
clinical benefit over placebo. For instance, it was recently
shown that the 6min walk distance in DMD patients is
predictive for the likelihood of losing ambulation in the next
year (Mazzone et al., 2013). As such, depending on the
design of the trial, patients likely to lose ambulation (or
unlikely to lose ambulation) can be included in the study.
This information should reduce the number of patients
needed to detect a significant difference in the primary
endpoint. Notably, there is no prescribed trial setup for exon
skipping trials, and regulators are open to an early discus-
sion on innovative trial designs, provided that these are
scientifically justified, have internal and external validity,
and apply the correct methodology to demonstrate clinically
relevant benefit for the patients.
One possible explanation for the phenotypic heterogene-
ity observed for most rare diseases is the presence of genetic
modifiers, which can influence disease progression by
modulating the outcome of the mutation; for example, lack
of the SMN1 gene causes spinal muscular atrophy, but de-
pending on the number of the homologous SMN2 genes
present, patients have a severe early onset disease, or a later
onset disease or are even asymptomatic (Taylor et al.,
1998). Genetic modifiers that influence disease progression
often are single-nucleotide polymorphisms (SNPs); for ex-
ample, for DMD, SNPs in LTBP4 and SPP1 genes (both
encoding proteins involved in the inflammatory response)
have been suggested to influence the age of loss of ambu-
lation (Pegoraro et al., 2011; Flanigan et al., 2013). For
SPP1, the major allele (allele frequency 0.88) was reported
to be protective in a recessive manner, while for LTBP4 the
minor haplotype (frequency *0.35) was reported to be
protective in a recessive manner. Both potential modifiers
have been reported to result in a 1-year difference in age of
loss of ambulation, which is a significant effect that may
influence trial results (Pegoraro et al., 2011; Flanigan et al.,
2013). However, because of low patient numbers, recruiting
patients for DMD exon skipping trials is challenging to
begin with, and excluding patients based on their genotype
for a (potential) genetic modifier would not be advisable.
Also, stratification will be challenging, because in relatively
small trials, it can be anticipated that sometimes only a
single patient will be homozygous for, for example, the
minor SPP1 allele.
It is also not yet known how the two reported potential
modifiers (SPP1 and LTBP4) influence each other. Fur-
thermore, it is very likely that there are additional genetic
modifiers that influence disease progression that have not
yet been identified. What can be done, however, is a retro-
spective post-hoc analysis based on genotype to investigate
whether there are significant differences (or trends) for the
different genotypic groups or to explain outliers who prog-
ress more (or less) quickly than other patients because of
their genotype.
Outcome Measures
Every positive opinion for granting a marketing authori-
zation adopted by the CHMP is based on the conclusion of a
positive benefit/risk ratio for the drug in question. The
demonstration that the observed effect leads to a clinically
relevant benefit for the patient plays a major part of this
positive benefit/risk conclusion. What clinical benefit entails
will obviously vary for different diseases, depending on
their symptoms and rate of disease progression. For DMD, a
30m difference in the 6min walking distance between
placebo-treated and drug-treated patients was proposed as
clinically relevant benefit (Henricson et al., 2013a), and
used in the recent Translarna CHMP positive opinion. As
mentioned earlier, the 6min walk test is predictive for when
patients may lose ambulation (Mazzone et al., 2013), and
it is known from treatment with corticosteroids that pro-
longed ambulation is associated with prolonged independent
breathing and survival, suggesting that the 30m difference
in the 6min walk test may reflect long-term impact on
disease progression. However, the 6min walk test cannot be
performed on nonambulatory DMD patients (who represent
the majority); for that reason, efforts to develop additional
functional scales, such as the ‘‘performance of upper limb
function,’’ are ongoing to allow designing clinical trials in
nonambulatory patients (Mayhew et al., 2013). These scales
may become acceptable to use as primary outcome measures
in clinical trials if the regulators are convinced that they are
indeed valid measures of a true clinical benefit.
Ideally, the results demonstrated for the primary endpoint
would be expected to be supported by the data from other
endpoints. Upon validation and acceptance of any newly
developed outcome measures, and given that the majority of
DMD patients are nonambulant, we may see future trials
performed in both ambulatory and nonambulatory patients,
888 AARTSMA-RUS ET AL.
even using different primary endpoints based on the baseline
disease status of the patients. In fact, pulmonary function
tests have been used as a primary outcome measure for a
phase 3 trial testing Idebenone (an antioxidant) in non-
ambulant DMD patients. However, for pulmonary function,
more insight in the rate of decline and effect of disease stage
in the contemporaneous, modified natural history of DMD is
needed to define clinical benefit as measured by respiratory
outcome measures.
It has become clear that while beneficial effects measured
through appropriate functional outcome measures are an in-
dispensable part of a successful marketing authorization, the
use of validated and qualified biomarkers may provide useful
additional information. In the regulatory sense, the term
‘‘biomarker’’ is not restricted to measures used to evaluate
and examine normal or pathogenic biological processes, or
pharmacologic responses to a therapeutic intervention, but
includes also innovative methods used specifically in the
context of research and development of new pharmaceuticals.
These methodologies can be used in a variety of different
ways, for example, to enrich a patient population for likely
responders, to show a pharmacodynamic confirmation of
activity (e.g., dystrophin restoration for DMD exon skipping),
or, if properly validated, to be used as primary endpoints in
the sense of surrogate endpoints.
Regardless of the intended purpose, these methodologies
need to undergo a regulatory qualification process, which in-
volves the analysis of data supporting the intended context of
use (i.e., for a biomarker to be used in a clinical trial as a
surrogate endpoint, data will need to be provided on the
correlation between the biomarker and outcome measure de-
tecting the expected clinical benefit). If the data are considered
sufficient, the methodology (biomarker) will be qualified and
become publically available for the intended context of use.
For DMD treatments aiming at dystrophin restoration,
dystrophin has historically been proposed as the logical pri-
mary (surrogate) endpoint, based on the fact that the lack of
the protein is the primary cause of the disease (lacking in
DMD patients and present in reduced levels in BMD patients)
and arguing that even its partial restoration is bound to bring
beneficial effects to the patients. However, in interventional
studies aiming at dystrophin restoration, data studying a
possible correlation between dystrophin levels and clinical
outcomes are currently unavailable (Aartsma-Rus, 2014b);
thus, the confirmation that an increase in dystrophin levels
indeed leads to a clinical benefit is currently lacking. One also
has to bear in mind that while in BMD patients low levels of
dystrophin are associated with a slower disease course, these
patients express dystrophin since birth. By contrast, DMD
patients express no or only very low levels of dystrophin
before they are treated, and consequently their muscle quality
will deteriorate with age. This is an additional reason why the
assumption that ‘‘any dystrophin increase in DMD patients is
bound to be clinically beneficial’’ first needs to be proven.
Although studies in animal models can offer predictive
values, only data obtained from clinical trials will be able to
reveal exactly what amounts of dystrophin are needed to
lead to clinical benefit, whether dystrophin restoration al-
ways leads to clinical benefit, whether the amount of dys-
trophin needed to achieve clinical benefit differs depending
on the muscle quality at the time of intervention, and
whether there is a ‘‘point of no return’’ when muscle quality
has deteriorated to such an extent that dystrophin restoration
does not lead to clinical benefit. Considering the above,
dystrophin levels cannot be regarded as a surrogate endpoint
for clinical efficacy in DMD patients. In cases where the
observed clinical efficacy is compelling and the clinical
benefit has been clearly demonstrated, data on dystrophin
production may not be required for approval, but when
available, such data and their correlation with clinical effi-
cacy outcomes would increase the robustness of the results.
However, dystrophin restoration can in all cases be used as a
pharmacodynamic marker, providing confirmation that the
applied therapeutic approach worked as predicted (Aartsma-
Rus, 2014b).
It is anticipated that patients with early stage disease will
benefit more from AON-mediated exon skipping than patients
with poorer muscle quality, since exon skipping targets dys-
trophin transcripts and these are expressed by muscle tissue
(and not by fibrotic or adipose tissues), and since dystrophin
restoration is expected to slow down disease progression, but
will not restore lost muscle tissue. Thus, methods to measure
muscle quality (e.g., magnetic resonance imaging) could be
developed to be used for selecting patients who are antici-
pated to be the best responders to a certain therapeutic ap-
proach, increasing the power of clinical trials. Furthermore,
patients with deletions bordering certain exons (e.g., exon 44)
or in certain areas of the gene (e.g., before exon 8) have been
found to have a more benign disease course, probably be-
cause a subset of these patients can produce very low amounts
of dystrophin because of spontaneous exon skipping or the
use of alternative initiation sites (Flanigan et al., 2009).
Indeed, patients involved in an exon 44 skipping trial
showed higher dystrophin levels at baseline than patients
involved in exon 51 skipping trials (Beekman et al., 2013).
Hence, a baseline dystrophin analysis could also be a pos-
sibility to stratify patients. Once it is known from currently
ongoing trials which patients respond best to treatment (e.g.,
based on muscle quality, baseline dystrophin levels, disease
trajectory, and genetic modifiers), it may be possible to
select the most appropriate patient population for future
trials, allowing for smaller and/or shorter trials without
compromising the quality of the outcome data.
However, stepping away from the specific example of
DMD and BMD, when developing drugs in rare diseases,
there is always a risk that testing a drug in very specific
subgroups may make extrapolation to the whole disease
population challenging. Currently, for a number of condi-
tions, efficacy data cannot be extrapolated from one disease
stage to another, as information is lacking that the demon-
strated clinical benefit in the narrow subpopulation will also
be relevant and bring about a positive benefit/risk ratio in a
population with a more progressed disease stage. Therefore,
it might be important that additional efficacy data be pro-
vided for the whole population, so that the benefit/risk ratio
for all potential subgroups of patients can be assessed by the
regulators and/or reimbursement bodies.
Regulatory Models for Marketing Approval
In EU various regulatory pathways are available for
achieving a centralized EU marketing authorization, which
include the full marketing authorization application, but also
the conditional marketing authorization and the marketing
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authorization under exceptional circumstances. Full marketing
authorization requires a comprehensive data package on clin-
ical benefit and safety to be present at the time of approval,
which can often be difficult in rare diseases because of limited
patient numbers and limited trial duration. Conditional mar-
keting authorization is a mechanism that allows approval for
drugs for severe and/or rare life-threatening diseases where
there is an unmet medical need. Here, data allowing the regu-
lators to conclude on a positive benefit/risk ratio at the time of
granting of the approval have to be provided as well, but ad-
ditional data that are crucial to the benefit/risk of the drug need
to be collected in the future in the form of postauthorization
commitments. The grantedmarketing authorization in this case
is conditional and will be re-evaluated on a yearly basis. Once
sufficient data have been collected, a company can apply and
convert this into a full marketing authorization.
Conditional authorization is a useful tool for rare dis-
eases, since it can provide earlier access to drugs for pa-
tients. However, since authorization is conditional, drugs
can technically be taken off the market if at any point during
the evaluation of the provided postapproval data, the benefit/
risk ratio turns negative, or the marketing authorization
holder fails to satisfactorily fulfill the postapproval com-
mitments (i.e., fails for whatever reason to provide the data
required in the ‘‘condition’’ of the marketing authorization).
An alternative approach for rare, debilitating, and life-
threatening diseases is presented by EMA’s pilot on adaptive
licensing.This is a processwhere a drug is authorizedearly for a
restricted group of patients (e.g., certain age range) based on
strong trends in the absence of safety issues, followed by
adaptive authorization for a wider group based on additional
evidence gathered (e.g., in younger or older patients). This
would be an attractive procedure for exon skipping therapies.
Finally, marketing authorization under exceptional circum-
stances is another mechanism that is specifically designed for
situations where it is impossible to acquire sufficient data in
clinical trials (e.g., becauseofvery limited patient populations).
Like with conditional marketing authorization, a yearly evalu-
ation of the benefit/risk ratio will take place; however, for ex-
ceptional marketing authorization, the additional information
obtained is not expected to ever lead to a full marketing autho-
rization. Exceptional marketing authorization may be a possi-
bility forAONs that apply only tovery small patient groups, but
probably only once marketing authorization has been obtained
for other AONs, thus confirming the therapeutic principle.
It is also possible for patients to gain early access to a drug
that has not yet obtained marketing authorization through
compassionate use programs. This applies only to drugs that
are in the development stage or subject of a marketing au-
thorization procedure. The regulations for compassionate use
differ per country; for example, the responsibility can lie with
the treating physician or the license holder, reimbursement
can be from the company, and the individual requesting
compassionate use or through a national system (e.g., tem-
porary authorizations for use in France) and reporting can
include adverse events and/or efficacy or only serious adverse
events. Compassionate use can be provided only during the
development of a drug if there is a reason to believe that it
would also be beneficial for a group of patients not included
in a clinical trial. However, once marketing authorization is
obtained in EU countries, compassionate use is no longer an
option for these countries.
Currently, each AON is considered a new drug by the
regulators (both when the AON target is identical but the
chemical modifications of the nucleotides differ, and when
the chemistry is identical but content and order of the nu-
cleotides differ). For the AON chemistries currently in clin-
ical trials for DMD, it is known that the pharmacokinetic,
pharmacodynamics, and safety profiles depend on the chem-
istry rather than the nucleotide order and composition of the
AON. Therefore, academics have proposed class approval for
a certain AON chemistry, which would avoid small trials in
which only a few patients could be included because of the
rarity of their mutations (e.g., exon 38 skipping would apply
to only 0.2% of DMD patients). However, this is unlikely to
be obtained for AONs in the near future, as class approval is
generally given when this is justifiable by a significant
amount of long-term data on safety and efficacy for a certain
class of drugs, while AONs are a relatively recent develop-
ment and only limited data are available for long-term safety
and efficacy. Nevertheless, preclinical data obtained for a
chemistry can of course be used for future AONs of the same
chemistry. Furthermore, it is probably possible to extrapolate
data on pharmacokinetics, pharmacodynamics, and safety
(being) obtained in past and ongoing clinical trials. As such,
it is likely that future AONs can be developed quicker.
The discussion on the possible ways to extrapolate data can
happen only when AONs have obtained marketing authori-
zation (which is currently not the case), and there are robust
data on at least one or two medicinal products, allowing the
regulators to conclude convincingly on their efficacy and
safety. Even then, extrapolation may be accepted only in
cases where the AONs have identical chemistries and are
used to treat the same disease. For each AON sequence,
specific data (e.g., on off-target effects) will also have to be
provided.
Extrapolation between diseases will be more difficult.
This is because clinical benefit is obviously not transferable
from one condition to another; for example, a 30m differ-
ence in 6min walk distance is considered a clinically sig-
nificant benefit for DMD patients, but this may not be the
case for less severely progressive muscular dystrophies.
Furthermore, while the safety profile is anticipated to be
similar for a certain AON chemistry regardless of the dis-
ease phenotype, its effect on the different populations may
lead to a different level of risk. For example, side effects
such as mild nephrotoxicity may create an acceptable risk in
view of the potential benefit for DMD patients (who in
general do not have disease-induced kidney damage), while
at the same time be completely unacceptable for a different
disease with pronounced disease-related kidney involve-
ment. So for each disease the balance between benefit and
risk will have to be evaluated, requiring a certain amount of
data that can be obtained only from clinical trials.
For DMD and other rare diseases, exon skipping some-
times would apply to only single patients. It may be possible
that small foundations or even individuals will develop these
AONs for individual patients. However, it is unlikely that
these AONs will be developed for marketing authorization,
and reimbursement will be challenging in most countries.
Since compassionate use is not possible for AONs that are
not in a clinical trial process, compassionate use is not a
mechanism to treat patients with new AONs applicable only to
small groups of patients that are not in clinical development.
890 AARTSMA-RUS ET AL.
Another complication for DMD exon skipping is that
19% of patients require the skipping of two exons to restore
the reading frame; for example, 0.3% would in theory
benefit from the skipping of exon 44 and exon 45, and 1.1%
from the skipping of exon 45 and exon 51. AONs to skip
these exons are in clinical development with potential plans
to apply for a marketing authorization for the combination
in the future. However, when this is done, additional tests
will be needed to provide data that patients treated with the
combination of AONs are not subjected to additional safety
risks. Furthermore, most probably, additional preclinical
tests would have to be conducted to optimize dosing. An
option currently being investigated is the possibility to re-
duce the dose of each individual AON and still obtain
double-exon skipping. However, since both AONs will have
to target the same transcript in order to restore the reading
frame, it is also conceivable that the dose of each individual
AON will have to be higher than for single-exon skipping.
If preclinical data suggest that double-exon skipping is
possible and safe, a postmarketing study where two AONs
are combined may be a possible way to assess the safety of
the combination. However, such speculations are too early
at present, and in the case of a combined AON therapy,
things are not as straightforward as just prescribing the two
individual AONs in patients. It is good to bear in mind that
double-exon skipping is an option for DMD because the
single-exon skipping by-products will not lead to a protein.
For other diseases, for example, epidermolysis bullosa, the
single-exon skipping by-products may actually be detri-
mental. Thus, it will have to be assessed on a case-by-case
basis whether double-exon skipping is an option.
Multiexon skipping (skipping of more than two exons) has
been proposed as a method to reduce the mutation specificity
of DMD exon skipping (Aartsma-Rus et al., 2004; Aoki et al.,
2013). Using a combination of 11 AONs targeting 11 exons,
the skipping of exons 45–55 should be induced. This would
apply to *40% of all patients with deletions or small mu-
tations between exons 45 and 55 (Aartsma-Rus et al., 2009).
An added benefit is that Becker patients with an exon 45–
55 deletion have a very mild phenotype (Beroud et al., 2007).
However, from a regulatory perspective, this multiexon
skipping would not be straightforward. First, there would be
safety concerns for combining any number of AONs (indi-
vidual AONs can be toxic and/or a combination of two or
more can be even more toxic). Second, multiexon skipping
will lead not only to the generation of exon 45–55 deleted
dystrophins, but also to many other in-frame and out-of-
frame versions (e.g., for a patient with an exon 48–50 dele-
tion, multiexon skipping can lead to dystrophins lacking
exons 45–51, exons 45–55, exons 47–51, exons 47–55, exons
48–51, exons 47–53, exons 48–53, exons 48–55, or com-
bined deletions of exons 45–46 plus exons 48–51, exons
48–53 or exons 48–55, or exons 54–55 plus exons 47–51 or
exons 48–51, in addition to an almost infinite list of out-of-
frame possibilities). Thus, multiexon skipping will dilute the
effect of AONs (it will generate more out-of-frame tran-
scripts than in-frame transcripts) and it will give rise to many
dystrophins that may not all be functional (this is especially
likely for the nonconsecutive in-frame deletions [e.g., exons
45–46 and exons 48–51]). This underlines that like double-
exon skipping, multiexon skipping is also not as straight-
forward as developing an ‘‘AON cocktail.’’ However, it is
possible that with new technical developments or AON
chemistries, multiexon skipping will be possible in the future.
Looking into the Future
AON-mediated exon skipping is a new type of therapeutic
approach that would be applicable to rare diseases. For DMD,
there has been a steep learning curve once AON-mediated exon
skipping, Translarna, and other therapies were tested in clinical
trials. Outcome measures were developed in parallel with the
trials and natural history data became available only during or
after phase 2 and 3 trials were conducted. Obviously, thiswas far
from ideal, and so it is advisable that groups developing exon
skipping for other rare diseases take outcome measures and
natural history into account from early phases of drug devel-
opment. Biomarkers to be used as pharmacodynamics markers
should be taken into account from an early stage as well.
Notably, at the moment no marketing authorization has
been granted to AON-mediated exon skipping for any dis-
ease. Nevertheless, it is anticipated that obtaining this for
the first AON will probably facilitate the development for
additional exon skipping AONs.
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